

**Prepared jointly with the  
World Health Organization (WHO)**

## **INN LIST 124 COVID-19 (Special Edition)**

### **Background**

The COVID-19 pandemic has increased research in new substances that could be helpful in the direct treatment against this unprecedented disease. On 20-21 August, the WHO convened a special meeting in view of the pressing need to give some new drug substances a name to be used and recognised worldwide in the hope that some of these substances will help in the pandemic.

As a result of this meeting, the WHO published on 26 October a new proposed INN List 124 COVID-19 (Special Edition) containing 25 substances pertinent to the COVID-19 pandemic.

If progress on the treatment of the COVID-19 disease is achieved with any of these substances, it would be expected that the movement of the relevant substance will increase across borders and therefore, their classification in the Harmonized System will indeed facilitate trade. Given the relevance of these substances, the WCO contacted the WHO with the idea to classify these substances and make the list available to Members.

The classification of the INN List 124 COVID-19 (special edition), as agreed by the Scientific Sub-Committee, is provided with a view to facilitating the classification of COVID-19 substances at the international level (6 digit of the HS).

The INN List 124 COVID-19 (Special Edition) can be found in the WHO website:

[https://www.who.int/medicines/publications/druginformation/issues/WHO\\_DI\\_34-3\\_PL124-SpecialEdition.pdf](https://www.who.int/medicines/publications/druginformation/issues/WHO_DI_34-3_PL124-SpecialEdition.pdf)

General Disclaimer:

*The WCO, the WHO Secretariats of the International Nonproprietary Name Programme and of the Model List of Essential Medicines, in view of the exceptional circumstances and the emergency due to the COVID-19 pandemic, are not in a position to verify the possible benefits and harms of the listed substances for the treatment of COVID-19, as well as the dosage.*

*The mention of specific substances does not imply that they are endorsed or recommended by WHO against COVID-19 or in the context of the COVID-19 pandemic. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO and WCO be liable for damages arising from its use.*

*The HS codes were provided by the WCO Secretariat with a view to facilitating the classification at the international level (6 digit of the HS) of the substances contained in the list. Economic operators are kindly advised to consult with the relevant Customs Administrations in relation to classification at domestic levels (7 or more digits) or in the event of any discrepancy between their practices and this list.*

**INN 124 LIST COVID-19 (Special Edition)**

<b>Product</b>	<b>HS 2017 Classification</b>
abdavomeran	3002.20
alunacedase alfa	3507.90
atibuclimab	3002.13
bamlanivimab	3002.13
casirivimab	3002.13
cilgavimab	3002.13
dazcapistat	2934.99
eclitasertib	2934.99
enpatoran	2933.49
etesevimab	3002.13
ganulameran	3002.20
goflikicept	3002.13
imdevimab	3002.13
molnupiravir	2934.99
nezulcitinib	2933.99
pemziviptadil	2937.19
pidacmeran	3002.20
regdanvimab	3002.13
reluscovtogene ralaplasmid	3002.20
sotrovimab	3002.13
subasumstat	2934.99
tixagevimab	3002.13
tozinameran	3002.20
zansecimab	3002.13
zorecimeran	3002.20